Answers are grounded in this paper and cite their sources.
This meta-analysis compares outcomes in uHCC, showing advantages of lenvatinib over bevacizumab, suggesting potential benefits for treatment.
In this meta-analysis of retrospective studies, lenvatinib plus PD-1/PD-L1 inhibitor regimens were associated with superior OS and PFS compared with bevacizumab plus PD-1/PD-L1 inhibitor regimens as first-line regimen for uHCC in East Asian populations. These findings require confirmation in large-scale, prospective, multinational randomized controlled trials in other populations.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: